Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis

Current Opinion in Oncology

Volumn 23, Issue 4, 2011, Pages 361-366

  Ravi, Vinod ^a   Wang, Wei Lien ^b   Lewis, Valerae O ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Pathology ^*  (United States)

Author keywords

CSF1R inhibitor; giant cell tumor of tendon sheath; pigmented villonodular synovitis; tenosynovial giant cell tumor

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; IMATINIB; JNJ 2831241; LINIFANIB; NILOTINIB; SUNITINIB; UNCLASSIFIED DRUG;

ARTHROSCOPY; CANCER CELL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; GIANT CELL TUMOR; HUMAN; IN SITU HYBRIDIZATION; INFLAMMATION; LYMPH NODE; MACROPHAGE; PATHOGENESIS; PIGMENTED VILLONODULAR SYNOVITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; REVIEW; SYNOVECTOMY; TENOSYNOVIAL GIANT CELL TUMOR;

ANTINEOPLASTIC AGENTS; GIANT CELL TUMORS; HUMANS; INDOLES; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; PIPERAZINES; PYRIMIDINES; PYRROLES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SOFT TISSUE NEOPLASMS; SYNOVIAL MEMBRANE; SYNOVITIS, PIGMENTED VILLONODULAR; TENDONS;

EID: 79958807634     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328347e1e3     Document Type: Review

References (40)

1. Jaffe HL, Lichtenstein L, Sutro CJ. Pigmented villonodular synovitis, bursitis and tenosynovitis. Archives of Pathology 1941; 21:731-765.
2. Dal Cin P, Sciot R, Samson I, et al. Cytogenetic characterization of tenosynovial giant cell tumors (nodular tenosynovitis). Cancer Res 1994; 54:3986-3987. (Pubitemid 24258097)
3. Weiss SW, Goldblum JR. Benign tumors and tumor-like lesions of synovial tissue. In: Weiss SW, Goldblum JR, editors. Enzinger and weiss's soft tissue tumors. Mosby Elsevier; 2008. p. 769.
4. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giantcell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103:690-695. (Pubitemid 43153087)
5. Brandal P, Bjerkehagen B, Heim S. Molecular cytogenetic characterization of tenosynovial giant cell tumors. Neoplasia 2004; 6:578-583. (Pubitemid 39411095)
6. Nilsson M, Hoglund M, Panagopoulos I, et al. Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors. Virchows Arch 2002; 441:475-480. (Pubitemid 35430463)
7. Sciot R, Rosai J, Dal Cin P, et al. Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: a report from the Chromosomes and Morphology (CHAMP) study group. Mod Pathol 1999; 12:576-579. (Pubitemid 29279709)
8. Monaghan H, Salter DM, Al-Nafussi A. Giant cell tumour of tendon sheath (localised nodular tenosynovitis): clinicopathological features of 71 cases. J Clin Pathol 2001; 54:404-407. (Pubitemid 32458143)
9. Huang GS, Lee CH, Chan WP, et al. Localized nodular synovitis of the knee: MR imaging appearance and clinical correlates in 21 patients. AJR 2003; 181:539-543. (Pubitemid 36909505)
10. Flandry F, Hughston JC. Pigmented villonodular synovitis. J Bone Joint Surg Am 1987; 69:942-949.
11. Ushijima M, Hashimoto H, Tsuneyoshi M, Enjoji M. Giant cell tumor of the tendon sheath (nodular tenosynovitis). A study of 207 cases to compare the large joint group with the common digit group. Cancer 1986; 57:875-884. (Pubitemid 16161072)
12. Mai MC, Demos TC, Lomasney LM, Harrington MA. The case: localized pigmented villonodular synovitis. Orthopedics 2006; 29:661; 737-40. (Pubitemid 44275505)
13. Rao AS, Vigorita VJ. Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases. J Bone Joint Surg Am 1984; 66:76-94. (Pubitemid 14186734)
14. Reilly KE, Stern PJ, Dale JA. Recurrent giant cell tumors of the tendon sheath. J Hand Surg Am 1999; 24:1298-1302.
15. Ottaviani S, Ayral X, Dougados M, Gossec L. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum (in press).
16. Myers BW, Masi AT. Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review. Medicine 1980; 59:223-238. (Pubitemid 10117857)
17. Somerhausen NS, Fletcher CD. Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am J Surg Pathol 2000; 24:479-492. (Pubitemid 30180741)
18. Chin KR, Barr SJ, Winalski C, et al. Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 2002; 84-A:2192-2202. (Pubitemid 35417699)
19. Mancini GB, Lazzeri S, Bruno G, Pucci G. Localized pigmented villonodular synovitis of the knee. Arthroscopy 1998; 14:532-536. (Pubitemid 28324054)
20. Moskovich R, Parisien JS. Localized pigmented villonodular synovitis of the knee. Arthroscopic treatment. Clin Orthop Relat Res 1991; 218-24.
21. Ogilvie-Harris DJ, McLean J, Zarnett ME. Pigmented villonodular synovitis of the knee. The results of total arthroscopic synovectomy, partial, arthroscopic synovectomy, and arthroscopic local excision. J Bone Joint Surg Am 1992; 74:119-123.
22. Zvijac JE, Lau AC, Hechtman KS, et al. Arthroscopic treatment of pigmented villonodular synovitis of the knee. Arthroscopy 1999; 15:613-617. (Pubitemid 29427179)
23. Chin KR, Brick GW. Extraarticular pigmented villonodular synovitis: a cause for failed knee arthroscopy. Clin Orthop Relat Res 2002; 330-338. (Pubitemid 35351088)
24. Byers PD, Cotton RE, Deacon OW, et al. The diagnosis and treatment of pigmented villonodular synovitis. J Bone Joint Surg Brit Vol1968; 50:290-305.
25. Johansson JE, Ajjoub S, Coughlin LP, et al. Pigmented villonodular synovitis of joints. Clin Orthop Relat Res 1982; 159-166. (Pubitemid 12188103)
26. Flandry FC, Hughston JC, Jacobson KE, et al. Surgical treatment of diffuse pigmented villonodular synovitis of the knee. Clin Orthop Relat Res 1994; 183-192. (Pubitemid 24085495)
27. Sharma V, Cheng EY. Outcomes after excision of pigmented villonodular synovitis of the knee. Clin Orthop Relat Res 2009; 467:2852-2858.
28. Chiari C, Pirich C, Brannath W, et al. What affects the recurrence and clinical outcome of pigmented villonodular synovitis? Clin Orthop Relat Res 2006; 450:172-178. (Pubitemid 44342132)
29. de Visser E, Veth RP, Pruszczynski M, et al. Diffuse and localized pigmented villonodular synovitis: evaluation of treatment of 38 patients. Arch Orthop Trauma Surg 1999; 119:401-404.
30. Horoschak M, Tran PT, Bachireddy P, et al. External beam radiation therapy enhances local control in pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 2009; 75:183-187.
31. O'Sullivan B, Cummings B, Catton C, et al. Outcome following radiation treatment for high-risk pigmented villonodular synovitis. Int J RadiatOncol Biol Phys 1995; 32:777-786.
32. Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19:821-822. (Pubitemid 351461057)
33. Ravi V, Wang W, Araujo DM, et al. Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. In: ASCO Annual Meeting; 2010; Chicago, Illinois. J Clin Oncol 2010; 28:15s (suppl; abstr 10011).
34. Cassier PA, Stacchiotti S, Gelderblom H, et al. Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). In: ASCO Annual Meeting; 2010; Chicago, Illinois. J Clin Oncol 2010; 28:15s (suppl; abstr 10012).
35. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20:757-766. (Pubitemid 38019277)
36. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804:445-453.
37. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006; 5:995-1006. (Pubitemid 43724600)
38. Guo J, Marcotte PA, McCall JO, et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006; 5:1007-1013. (Pubitemid 43724601)
39. Manthey CL, Johnson DL, Illig CR, et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 2009; 8:3151-3161.
40. Scott DA, Dakin LA, Del Valle DJ, et al. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor. Bioorg Med Chem Lett 2011; 21:1382-1384.